Benchmark lowered the firm’s price target on Cross Country Healthcare to $24 from $31 and keeps a Buy rating on the shares following a Q3 AEBITDA miss and Q4 guidance that was below consensus. While management believes it can maintain high single digit AEBITDA margins in 2024 even without significant improvement in gross margin, the firm’s updated model assumes only modest improvement in 2024 from Q4 of 2023, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CCRN:
- Cross Country Healthcare sees Q4 adjusted EPS 25c-35c, consensus 45c
- Cross Country Healthcare reports Q3 adjusted EPS 39c, consensus 41c
- CCRN Upcoming Earnings Report: What to Expect?
- Cross Country Healthcare price target lowered to $32 from $40 at Jefferies
- Cross Country Healthcare management to meet with Truist
